Chargement des cours...

Prévisions

Acheter
  3
Conserver
  3
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Evotec scales back restructuring further, 2030 revenue target cut to around €1bn

    Evotec reports that the cost-saving program "Horizon" is progressing faster than planned and has already realized just over one-fifth of the savings expected by the end of 2027; the goal is to reduce the cost base by €75m and to close four plants with up to 800 job cuts (about half already carried out). The medium-term revenue forecast was lowered to around €1bn by 2030, though CEO Christian Wojczewski sees the potential for another billion if partner development improves. In the first nine months, revenue fell by about 13% to roughly €465m, adjusted EBITDA was -€44.3m and the net loss about €195m; full-year revenue is expected to be €570–610m. The stock is up more than 5% today and broke the 50-day line, but the company must continue to deliver to achieve a sustainable turnaround. » Plus sur deraktionaer.de


  • Evotec appoints Joanna Holbrook from Novo Nordisk as chief scientific officer

    Evotec is appointing Joanna Holbrook to the executive board and as chief scientific officer effective 1 November 2026; she brings more than 25 years of experience in omics, data sciences, novel therapeutics and precision medicine. Holbrook joins from Novo Nordisk, where she served, among other roles, as therapy area head for cardiovascular, renal and liver diseases and as head of in vitro discovery platforms. The appointment supported the stock in the short term, but for a sustainable turnaround Evotec must clearly improve profitability. » Plus sur deraktionaer.de


  • Evotec beats analysts' expectations for nine months and stock rises

    Evotec reports revenue of 465.0 million euros and an adjusted negative EBITDA of 42.8 million euros for the first nine months, both better than analysts had expected. The management board leaves the July-lowered full-year guidance unchanged at 570–610 million euros in revenue and an adjusted EBITDA of -70 to -105 million euros. The share price rose by nearly seven percent after the figures, but remains substantially down year-to-date. » Plus sur finanzen.net


  • Evotec confirms lowered annual forecast: revenue target €570–610 million

    Evotec stands by the annual forecast it lowered in mid‑July and expects revenue of €570 to €610 million. Adjusted EBITDA is forecast at between minus €70 million and minus €105 million. For the first nine months the company expects revenue of €465.0 million and adjusted EBITDA of minus €42.8 million, which is above current market expectations and is mainly attributed to the timing of consensus estimates. » Plus sur finanzen.net


  • EVOTEC stabilizes after share-price slump despite lowered guidance and restructuring costs

    After a sharp share-price slump, EVOTEC stock is showing first signs of recovery but remains under pressure due to the sales forecast for 2026 being cut (€570–610m) and an expected adjusted EBITDA loss. The cost-saving program Horizon is intended to save around €75m annually from late 2027, but will cause one-off cash costs of about €100m and 800 job cuts in the near term. A current strategic review and personnel changes add uncertainty, although net order intake in the core business has risen and liquidity still appears solid for now. Investors should watch the next quarterly results, liquidity development and concrete progress on Horizon. » Plus sur finanzen.net

Données financières de l'entreprise

Au dernier trimestre, Evotec a réalisé un chiffre d'affaires de 164,93 M € et un bénéfice net de -26,74 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 164,93 M 0,63 %
Bénéfice brut 19,8 M 32 027,42 %
Bénéfice net -26,74 M 37,93 %
EBITDA -18,12 M 2,70 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
529,08 M €
Nombre d'actions
177,19 M
Plus haut/bas sur 52 semaines
6,68 € - 2,41 €
Dividendes Non
Bêta
1,08
Ratio P/E
-2,92
Ratio PEG
0,04
Ratio P/B
0,82
Ratio P/S
0,74

Profil de l'entreprise

Evotec SE exerce une activité de partenaire en découverte et développement de médicaments pour l'industrie pharmaceutique et biotechnologique dans le monde entier. La société développe des produits pharmaceutiques dans divers domaines thérapeutiques, tels que le diabète et les complications du diabète, la fibrose, les maladies infectieuses, les maladies du système nerveux central, l'oncologie, la douleur et l'inflammation, l'immunologie, les maladies rares, les maladies respiratoires et la santé des femmes. Elle a conclu des accords de collaboration avec Bayer AG ; Lilly ; Chinook Therapeutics ; Novo Nordisk A/S ; Galapagos ; Pfizer Inc. ; CONBA Pharmaceutical Co., Ltd. ; Bristol Myers Squibb Company ; Zhejiang JingXin Pharmaceutical Co., Ltd ; Kazia Therapeutics ; Apeiron Biologics ; et Takeda Pharmaceuticals. La société était auparavant connue sous le nom d'Evotec AG et a changé sa dénomination en Evotec SE en avril 2019. Evotec SE a été constituée en 1993 et a son siège social à Hambourg, en Allemagne.

Nom
Evotec
PDG
Christian Wojczewski
Siège social Hamburg, ha
Allemagne
Site web
Secteur
Santé
Industrie
Biotechnologie
Introduction en bourse
12/11/1999
Employés 4 553

Symboles boursiers

Bourse Symbole
Iob
0IRF.IL
XETRA
EVT.DE
Pnk
EVOTF
SIX
EVT.SW
Frankfurt
EVT.F
Düsseldorf
EVT.DU
Hamburg
EVT.HM
Milan
1EVT.MI
London
0IRF.L
München
EVT.MU
Wien
EVT.VI
🍪

Parqet  utilise des cookies. En savoir plus